JP2018515557A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018515557A5 JP2018515557A5 JP2017560314A JP2017560314A JP2018515557A5 JP 2018515557 A5 JP2018515557 A5 JP 2018515557A5 JP 2017560314 A JP2017560314 A JP 2017560314A JP 2017560314 A JP2017560314 A JP 2017560314A JP 2018515557 A5 JP2018515557 A5 JP 2018515557A5
- Authority
- JP
- Japan
- Prior art keywords
- esketamine
- pharmaceutical composition
- composition according
- during
- dosage unit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YQEZLKZALYSWHR-ZDUSSCGKSA-N (S)-ketamine Chemical compound C=1C=CC=C(Cl)C=1[C@@]1(NC)CCCCC1=O YQEZLKZALYSWHR-ZDUSSCGKSA-N 0.000 claims description 54
- 229960000450 esketamine Drugs 0.000 claims description 54
- 230000006698 induction Effects 0.000 claims description 40
- 238000000034 method Methods 0.000 claims description 28
- 238000012423 maintenance Methods 0.000 claims description 20
- 208000028552 Treatment-Resistant Depressive disease Diseases 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 238000007918 intramuscular administration Methods 0.000 claims description 2
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000000902 placebo Substances 0.000 claims description 2
- 229940068196 placebo Drugs 0.000 claims description 2
- 238000007920 subcutaneous administration Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 27
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562164026P | 2015-05-20 | 2015-05-20 | |
| US62/164,026 | 2015-05-20 | ||
| PCT/US2016/033404 WO2016187491A1 (en) | 2015-05-20 | 2016-05-20 | Methods and kits for treating depression |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018515557A JP2018515557A (ja) | 2018-06-14 |
| JP2018515557A5 true JP2018515557A5 (https=) | 2019-06-13 |
Family
ID=57320901
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017560314A Pending JP2018515557A (ja) | 2015-05-20 | 2016-05-20 | うつ病を治療するための方法及びキット |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20160338977A1 (https=) |
| EP (1) | EP3297618A4 (https=) |
| JP (1) | JP2018515557A (https=) |
| KR (1) | KR20180008634A (https=) |
| CN (1) | CN107735081A (https=) |
| AU (3) | AU2016263598A1 (https=) |
| CA (1) | CA2986477A1 (https=) |
| CL (1) | CL2017002904A1 (https=) |
| CO (1) | CO2017011564A2 (https=) |
| DO (1) | DOP2017000268A (https=) |
| EA (1) | EA201792545A1 (https=) |
| EC (1) | ECSP17077930A (https=) |
| GT (1) | GT201700246A (https=) |
| HK (1) | HK1252937A1 (https=) |
| IL (1) | IL255463A (https=) |
| MA (1) | MA42135A (https=) |
| MX (1) | MX2017014797A (https=) |
| PE (1) | PE20180260A1 (https=) |
| PH (1) | PH12017502103A1 (https=) |
| WO (1) | WO2016187491A1 (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140274981A1 (en) | 2013-03-15 | 2014-09-18 | Janssen Pharmaceutica Nv | Pharmaceutical composition of s-ketamine hydrochloride |
| KR20170040800A (ko) | 2014-08-13 | 2017-04-13 | 얀센 파마슈티카 엔.브이. | 우울증 치료 방법 |
| AU2015318123A1 (en) | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
| US20160332962A1 (en) | 2015-05-13 | 2016-11-17 | Janssen Pharmaceutica Nv | (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine |
| CN107847469A (zh) | 2015-06-27 | 2018-03-27 | 美国神农制药责任有限公司 | 氯胺酮透皮递送系统 |
| US20200009081A1 (en) | 2017-09-13 | 2020-01-09 | Janssen Pharmaceutica N.V. | Delivery Of Esketamine For The Treatment Of Depression |
| KR20240011237A (ko) * | 2017-12-22 | 2024-01-25 | 얀센 파마슈티카 엔브이 | 우울증 치료를 위한 에스케타민 |
| ES2907692T3 (es) | 2017-12-29 | 2022-04-26 | Celon Pharma Sa | Composición de ketamina de polvo seco para su administración por vía pulmonar en la depresión resistente al tratamiento |
| BR112020023882A2 (pt) * | 2018-06-27 | 2021-02-09 | Clexio Biosciences Ltd. | método para tratar transtorno depressivo maior |
| EP3628313B1 (en) * | 2018-09-28 | 2025-02-12 | Novohale Therapeutics, LLC | Ketamine composition for use in a method of treatment of depression by pulmonary administration |
| WO2020070547A1 (en) * | 2018-10-05 | 2020-04-09 | Clexio Biosciences Ltd. | Dosage regime of esketamine for treating major depressive disorder |
| CN112702995A (zh) * | 2018-10-05 | 2021-04-23 | 克雷西奥生物科技有限公司 | 治疗重度抑郁症的艾氯胺酮的治疗方案 |
| EP3863617A1 (en) | 2018-10-11 | 2021-08-18 | Clexio Biosciences Ltd. | Esketamine for use in treating major depressive disorder |
| JP2022524008A (ja) * | 2019-03-05 | 2022-04-27 | ヤンセン ファーマシューティカルズ，インコーポレーテッド | うつ病の治療のためのエスケタミン |
| CN114286674A (zh) * | 2019-08-28 | 2022-04-05 | 杨森制药公司 | 用于治疗患有包括自杀倾向在内的重性抑郁障碍的患者的艾司氯胺酮 |
| TW202135787A (zh) | 2019-12-12 | 2021-10-01 | 比利時商健生藥品公司 | 艾氯胺酮調配物及製備與儲存的方法 |
| EP4084786A1 (en) | 2019-12-30 | 2022-11-09 | Clexio Biosciences Ltd. | Dosage regime with esketamine for treating major depressive disorder |
| JP2023507926A (ja) | 2019-12-30 | 2023-02-28 | クレキシオ バイオサイエンシーズ エルティーディー． | 神経精神状態または神経学的状態を治療するためのエスケタミンを用いた投与計画 |
| JP7840873B2 (ja) * | 2020-05-28 | 2026-04-06 | ヤンセン ファーマシューティカ エヌ．ベー． | うつ病の治療方法 |
| GB202019952D0 (en) * | 2020-12-17 | 2021-02-03 | Neurocentrx Pharma Ltd | Novel compositions |
| WO2022235576A1 (en) * | 2021-05-03 | 2022-11-10 | Wang Michael Z | Methods and compositions for treating depression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007229866A1 (en) * | 2006-03-22 | 2007-10-04 | Mount Sinai School Of Medicine | Intranasal administration of ketamine to treat depression |
| US20110038807A1 (en) * | 2009-08-14 | 2011-02-17 | Demitri Papolos | Compositions and methods for treating bipolar disorder |
| WO2013003669A2 (en) * | 2011-06-30 | 2013-01-03 | University Of South Florida | Compositions, methods of use, and methods of treatment |
| WO2013138322A1 (en) * | 2012-03-12 | 2013-09-19 | Janssen Pharmaceutica Nv | Esketamine for the treatment of treatment-refractory or treatment-resistant depression |
| EP2830604A4 (en) * | 2012-03-30 | 2015-08-19 | Gen Hospital Corp | COMPOSITIONS WITH SCOPOLAMINE AND KETAMINE FOR THE TREATMENT OF DEPRESSIONS |
| DK2983787T3 (da) * | 2013-04-12 | 2020-01-06 | Icahn School Med Mount Sinai | Fremgangsmåde til behandling af posttraumatisk stresssygdom |
| AU2015318123A1 (en) * | 2014-09-15 | 2017-03-30 | Janssen Pharmaceutica Nv | Val66Met (SNP rs6265) genotype specific dosing regimens and methods for the treatment of depression |
-
2016
- 2016-05-19 US US15/159,257 patent/US20160338977A1/en not_active Abandoned
- 2016-05-20 EA EA201792545A patent/EA201792545A1/ru unknown
- 2016-05-20 HK HK18112292.0A patent/HK1252937A1/zh unknown
- 2016-05-20 AU AU2016263598A patent/AU2016263598A1/en not_active Abandoned
- 2016-05-20 CA CA2986477A patent/CA2986477A1/en not_active Abandoned
- 2016-05-20 JP JP2017560314A patent/JP2018515557A/ja active Pending
- 2016-05-20 KR KR1020177036002A patent/KR20180008634A/ko not_active Withdrawn
- 2016-05-20 PE PE2017002425A patent/PE20180260A1/es unknown
- 2016-05-20 CN CN201680029082.XA patent/CN107735081A/zh active Pending
- 2016-05-20 WO PCT/US2016/033404 patent/WO2016187491A1/en not_active Ceased
- 2016-05-20 MX MX2017014797A patent/MX2017014797A/es unknown
- 2016-05-20 MA MA042135A patent/MA42135A/fr unknown
- 2016-05-20 EP EP16797348.6A patent/EP3297618A4/en not_active Withdrawn
-
2017
- 2017-11-06 IL IL255463A patent/IL255463A/en unknown
- 2017-11-14 CO CONC2017/0011564A patent/CO2017011564A2/es unknown
- 2017-11-15 CL CL2017002904A patent/CL2017002904A1/es unknown
- 2017-11-16 GT GT201700246A patent/GT201700246A/es unknown
- 2017-11-17 DO DO2017000268A patent/DOP2017000268A/es unknown
- 2017-11-20 PH PH12017502103A patent/PH12017502103A1/en unknown
- 2017-11-23 EC ECIEPI201777930A patent/ECSP17077930A/es unknown
-
2021
- 2021-08-11 AU AU2021215155A patent/AU2021215155A1/en not_active Abandoned
-
2023
- 2023-09-25 AU AU2023237026A patent/AU2023237026A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018515557A5 (https=) | ||
| JP2017528483A5 (https=) | ||
| JP2020002171A5 (https=) | ||
| JP2018138603A5 (https=) | ||
| JP2017503820A5 (https=) | ||
| MX2023012450A (es) | Esketamina para el tratamiento de la depresion. | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2016540738A5 (https=) | ||
| SI2625199T1 (en) | Procedures for treating psoriasis using IL-17 antagonists | |
| EA201490748A1 (ru) | Лечение рассеянного склероза комбинацией лахинимода и финголимода | |
| JP2015187125A5 (https=) | ||
| EA201490378A1 (ru) | ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β | |
| EA201990558A3 (ru) | Доставка нацеленных на экзон 2 полинуклеотидных конструкций u7snrna при помощи рекомбинантного аденоассоциированного вируса | |
| JP2013505205A5 (https=) | ||
| NO20091826L (no) | Fremgangsmater for dosering av oralt aktive 1,2,4-oksadiazol for nonsense mutasjonsuppresjonsterapi | |
| NZ707640A (en) | Treatment or prevention of cardiovascular events via the administration of a colchicine derivative | |
| JP2015505564A5 (https=) | ||
| JP2019501886A5 (https=) | ||
| JP2017160178A5 (https=) | ||
| JP2017513809A5 (https=) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| UA105191C2 (ru) | Лечение пирфенидоном пациентов с атипической функцией печени | |
| EA202190429A1 (ru) | Биодоступные пероральные дозированные формы | |
| JP2016515137A5 (https=) | ||
| JP2019507786A5 (https=) |